147 related articles for article (PubMed ID: 17433038)
1. Myeloid suppressor cell-associated immune dysfunction in CSA1M fibrosarcoma tumor-bearing mice.
Zhou R; He PL; Ren YX; Wang WH; Zhou RY; Wan H; Ono S; Fujiwara H; Zuo JP
Cancer Sci; 2007 Jun; 98(6):882-9. PubMed ID: 17433038
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor-beta (TGF-beta)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-beta and a progressive increase in TGF-beta susceptibility of anti-tumor CD4+ T cell function.
Li XF; Takiuchi H; Zou JP; Katagiri T; Yamamoto N; Nagata T; Ono S; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1993 Mar; 84(3):315-25. PubMed ID: 8098027
[TBL] [Abstract][Full Text] [Related]
3. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells.
Zou JP; Yamamoto N; Fujii T; Takenaka H; Kobayashi M; Herrmann SH; Wolf SF; Fujiwara H; Hamaoka T
Int Immunol; 1995 Jul; 7(7):1135-45. PubMed ID: 8527411
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms underlying IFN-gamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12.
Yu WG; Yamamoto N; Takenaka H; Mu J; Tai XG; Zou JP; Ogawa M; Tsutsui T; Wijesuriya R; Yoshida R; Herrmann S; Fujiwara H; Hamaoka T
Int Immunol; 1996 Jun; 8(6):855-65. PubMed ID: 8671675
[TBL] [Abstract][Full Text] [Related]
5. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice.
Bronte V; Serafini P; De Santo C; Marigo I; Tosello V; Mazzoni A; Segal DM; Staib C; Lowel M; Sutter G; Colombo MP; Zanovello P
J Immunol; 2003 Jan; 170(1):270-8. PubMed ID: 12496409
[TBL] [Abstract][Full Text] [Related]
6. Reduction of myeloid suppressor cell derived nitric oxide provides a mechanistic basis of lead enhancement of alloreactive CD4(+) T cell proliferation.
Farrer DG; Hueber S; Laiosa MD; Eckles KG; McCabe MJ
Toxicol Appl Pharmacol; 2008 Jun; 229(2):135-45. PubMed ID: 18433816
[TBL] [Abstract][Full Text] [Related]
7. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation.
Kusmartsev SA; Li Y; Chen SH
J Immunol; 2000 Jul; 165(2):779-85. PubMed ID: 10878351
[TBL] [Abstract][Full Text] [Related]
8. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer.
Feng PH; Lee KY; Chang YL; Chan YF; Kuo LW; Lin TY; Chung FT; Kuo CS; Yu CT; Lin SM; Wang CH; Chou CL; Huang CD; Kuo HP
Am J Respir Crit Care Med; 2012 Nov; 186(10):1025-36. PubMed ID: 22955317
[TBL] [Abstract][Full Text] [Related]
9. Differential modulation of CD4 and CD8 T-cell proliferation by induction of nitric oxide synthesis in antigen presenting cells.
Hoffman RA; Mahidhara RS; Wolf-Johnston AS; Lu L; Thomson AW; Simmons RL
Transplantation; 2002 Sep; 74(6):836-45. PubMed ID: 12364865
[TBL] [Abstract][Full Text] [Related]
10. IL-7 inhibits tumor growth by promoting T cell-mediated antitumor immunity in Meth A model.
Tang JC; Shen GB; Wang SM; Wan YS; Wei YQ
Immunol Lett; 2014; 158(1-2):159-66. PubMed ID: 24406503
[TBL] [Abstract][Full Text] [Related]
11. Suppression of anti-tumor CD4+ T cell responsiveness in the tumor-bearing state and its recovery in in vitro culture free of tumor burden.
Nagata T; Zou JP; Yamamoto N; Ono S; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1993 Nov; 84(11):1181-9. PubMed ID: 7903964
[TBL] [Abstract][Full Text] [Related]
12. Sca1(+)/Mac1(+) nitric oxide-producing cells in the spleens of recipients early following bone marrow transplant suppress T cell responses in vitro.
Johnson BD; Hanke CA; Becker EE; Truitt RL
Cell Immunol; 1998 Nov; 189(2):149-59. PubMed ID: 9790729
[TBL] [Abstract][Full Text] [Related]
13. Recovery of antitumor CD4+ T cell responsiveness, suppressed in the tumor-bearing state, by release from tumor burden.
Zou JP; Nagata T; Yamamoto N; Ono S; Fujiwara H; Hamaoka T
J Cancer Res Clin Oncol; 1994; 120(5):279-85. PubMed ID: 7907334
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte-mediated macrophage apoptosis during IL-12 stimulation.
Yim JY; Yang SJ; Yim JM; Song MY; Rho HW; Yim SK; Han YH; Jeon SY; Kim HS; Yhim HY; Lee NR; Song EK; Kwak JY; Sohn MH; Yim CY
Cytokine; 2013 Oct; 64(1):62-70. PubMed ID: 23953854
[TBL] [Abstract][Full Text] [Related]
15. IL-12-induced tumor regression correlates with in situ activity of IFN-gamma produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways.
Yu WG; Ogawa M; Mu J; Umehara K; Tsujimura T; Fujiwara H; Hamaoka T
J Leukoc Biol; 1997 Oct; 62(4):450-7. PubMed ID: 9335314
[TBL] [Abstract][Full Text] [Related]
16. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism.
Mazzoni A; Bronte V; Visintin A; Spitzer JH; Apolloni E; Serafini P; Zanovello P; Segal DM
J Immunol; 2002 Jan; 168(2):689-95. PubMed ID: 11777962
[TBL] [Abstract][Full Text] [Related]
17. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.
Mundy-Bosse BL; Lesinski GB; Jaime-Ramirez AC; Benninger K; Khan M; Kuppusamy P; Guenterberg K; Kondadasula SV; Chaudhury AR; La Perle KM; Kreiner M; Young G; Guttridge DC; Carson WE
Cancer Res; 2011 Aug; 71(15):5101-10. PubMed ID: 21680779
[TBL] [Abstract][Full Text] [Related]
18. Increased sensitivity of tumor-bearing host macrophages to interleukin-10: a counter-balancing action to macrophage-mediated suppression.
Alleva DG; Burger CJ; Elgert KD
Oncol Res; 1994; 6(4-5):219-28. PubMed ID: 7841545
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of anti-cancer and immunomodulatory effects of carnosol in a Balb/c WEHI-164 fibrosarcoma model.
Rahnama M; Mahmoudi M; Zamani Taghizadeh Rabe S; Balali-Mood M; Karimi G; Tabasi N; Riahi-Zanjani B
J Immunotoxicol; 2015; 12(3):231-8. PubMed ID: 25027673
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
Suzuki E; Kapoor V; Jassar AS; Kaiser LR; Albelda SM
Clin Cancer Res; 2005 Sep; 11(18):6713-21. PubMed ID: 16166452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
